Class Action Filed Alleging Investor Harm Against Chemours Company
A class action lawsuit alleging investor harm has been filed against Chemours Company.
Related stories
Nasdaq to Delist Aldel Financial II After Listing Rule Breach
Nasdaq notified Aldel Financial II that its securities will be delisted after the company failed to comply with Listing Rule 5450(a)(2) and missed the deadline to submit a complian
M impact | REGULATION | Oct 29, 2026, 09:23 PM UTC
Nasdaq to Delist Glucotrack After Listing-Rule Exception Failure
Nasdaq notified Glucotrack on October 28 that its securities would be delisted after the closing bid price fell to $0.87 on October 14, failing the terms of an exception to Nasdaq
M impact | REGULATION | Oct 29, 2026, 09:05 PM UTC
Propanc Biopharma Receives Nasdaq Delisting Notice
Nasdaq said Propanc Biopharma failed to meet the $1.00 minimum bid price requirement and is ineligible for a standard compliance period following a recent reverse stock split.
M impact | REGULATION | Oct 29, 2026, 09:03 PM UTC
Nasdaq Notifies Charming Medical of Potential Delisting Nov. 9
Nasdaq says Charming Medical will be delisted on November 9, 2026, unless the company appeals.
M impact | REGULATION | Oct 29, 2026, 08:54 PM UTC
US Promises Tariff Relief in Talks With Audi Over Georgia Plant, Sources Say
M impact | REGULATION | Oct 29, 2026, 08:38 PM UTC
Greek PM Reaffirms Support for Sanctions on Russia
M impact | REGULATION | Oct 29, 2026, 08:36 PM UTC